Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice

ASH 2024

Lymphoma

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

ESMO 2024

Lymphoma

Tisa-cel demonstrates high efficacy and manageable safety profile in patients with R/R follicular lymphoma

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Lymphoma

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

Related content

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Tisa-cel demonstrates high efficacy and manageable safety profile in patients with R/R follicular lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL